| A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit | |
| Jiang, Zefei; Zhang, Qingyuan; Shao, Zhimin; Shen, Kunwei; Li, Li; Feng, Jifeng; Tong, Zhongseng; Gu, Kangsheng; Wang, Xiaojia; Xu, Binghe | |
| 2015 | |
| 会议名称 | CANCER RESEARCH |
| 会议日期 | 2015-05-01 |
| 收录类别 | CPCI-S |
| URL标识 | 查看原文 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6386262 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Jiang, Zefei,Zhang, Qingyuan,Shao, Zhimin,et al. A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit[C]. 见:CANCER RESEARCH. 2015-05-01. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论